Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued ...

GSA Capital Partners LLP cut its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 44.9% during the third quarter, according to the company in its most recent ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript November 7, 2024 Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Aurinia Pharmaceuticals Inc. announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support ...

Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

Jeffrey Allen Bailey, a director at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), recently reported a sale of company stock. According to a filing with the Securities and Exchange Commission ...

Aurinia (AUPH) stock jumped 14% Thursday after the company reported better-than-expected Q3 revenue and announced it was ...